It is expected that this will lead to a broader therapeutic window of HDAC inhibitors, and possibly to a clinical application in non-oncological disease states. Histone acetylation is a dynamic ...

Shuttle Pharma receives US patent for selective histone deacetylase inhibitors for the treatment of human disease: Gaithersburg, Maryland Monday, September 9, 2024, 17:00 Hrs [IST ...

Researchers at the University of Alabama at Birmingham discovered that combining regorafenib with a dual JAK/HDAC inhibitor ...

The patent covers selective histone deacetylase (HDAC) inhibitors designed to regulate genes involved in cancer progression, immune responses, and other biological processes. These inhibitors are ...

Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the ...

6, 2023 — Researchers discovered how anti-cancer drugs called HDAC inhibitors help treat pancreatic cancer by altering scar tissue (fibroblast) development. The findings suggest HDAC inhibitors ...

It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response ...

Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg12O12 and Zn12O12 nanoclusters: an in silico strategy for COVID-19 treatment.

Citation: PARP1 selective inhibitor yields potent and durable antitumor activity in patient-derived preclinical models (2024, September 3) retrieved 19 September 2024 from https://medicalxpress ...